Skip to main content
Top

Arthritis Research & Therapy

Issue Special Issue 2/2003

1st Workshop of the International Society for Behçet's Disease (ISBD) on Pathophysiology and Treatment of Behçet's Disease

Content (13 Articles)

Meeting abstract

Introduction

CG Barnes

Meeting abstract

Cytotoxic drugs in ocular lesions of Behçet's disease

F Davatchi, F Shahram, H Chams, A Nadji, AR Jamshidi, C Chams, M Akbarian, F Gharibdoost, M Sedigh, B Sadeghi

Meeting abstract

The use of interferon-alfa in Behçet's disease: review of the literature

I Kötter, I Günaydin, M Zierhut, N Stübiger

Meeting abstract

Efficacy of recombinant human interferon-alfa2a on ocular and extra-ocular manifestations of Behçet's disease and influence on cells of the immune system: results of an open four center trial

I Kötter, M Treusch, R Vonthein, M Zierhut, A Eckstein, T Ness, I Günaydin, B Grimbacher, S Blaschke, HH Peter, N Stübiger

Meeting abstract

TNF and anti-TNF agents in Behçet's disease

KT Calamia

Meeting abstract

Migration of dendritic cells into the lymphatics: the Langerhans cell example

N Romani, P Stoitzner, S Ebner, H Stössel, S Holzmann, G Ratzinger, P Fritsch

Meeting abstract

Viral infection of retinal pigment epithelium: a possible role for initiation of Behçet's disease

EU Irschick, HP Huemer, C Larcher, R Sgonc, W Göttinger

Meeting abstract

Immunosuppressive effects of gemcitabine in the HSV-induced Behçet's disease like mouse model

S Sohn, M Lutz, HJ Kwon, G Konwalinka, S Lee, M Schirmer

Meeting abstract

Streptococcal antigen in the pathogenesis of Behçet's disease

F Kaneko, H Yanagihori, M Tojo, E Isogai, SN Lin, K Oguma

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine